Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
CIC2000 Dr. Peter Estibeiro: Co-Founder and Director ExpressOn BioSystems Access to molecular technology Products and services for the cutting edge of bio-science research and therapeutics An improved process for the rapid and efficient design of antisense reagents that can cut lead drug development time by over 50% and initial drug development costs from an average £70 million to around £5 million enabling us to address the estimated £900 million market for gene therapy products [USADATA.COM] ExpressOn BioSystems Acces s t o m olecu la r t ech n ology What do antisense reagents do? antisense reagent DNA RNA protein ExpressOn BioSystems Acces s t o m olecu la r t ech n ology Why are antisense reagents useful? •Pure and Applied Research Used as research tools to understand gene function Used for drug target validation Human Genome Mapping Project will increase the number of potential drug targets from 500 to 10,000 by 2010 •Therapeutics Emerging drugs for difficult-to-treat diseases FDA approval for first antisense drug in 1998 Heralded as the most important medical advance since antibiotics ExpressOn BioSystems Acces s t o m olecu la r t ech n ology What is our improved design process? A DNA microarray & proprietary analysis software Can be used on standard microarray readers Why is it so good? •Rapid applicable to mass screening able to cope with number of new targets •Efficient higher success rate than computer-aided design reduced downstream testing •Cheap uses established equipment & manufacturing processes ExpressOn BioSystems Acces s t o m olecu la r t ech n ology Staged roll-out to market Target Customers Market Size Market Niche Market Share Drug target validation (service) Major pharma R&D depts £2.5 B UK annual pharma UK spend Leader within 2 years Drug therapy candidates (licences &/or partnerships) Major pharma Drug development programmes Application £900 M for noncancer gene therapies Brain First to diseases market eg. AD epilepsy stroke ExpressOn BioSystems Acces s t o m olecu la r t ech n ology Why will we succeed? •Rapid, cheap and effective design process •Aggressive share of specific market niches geographical (UK) biological (brain function) •Scientific expertise advisory panel of leading neuroscientists •Staged roll-out provides revenue during drug development •Already a successful company providing contract research services in molecular biology ExpressOn BioSystems Acces s t o m olecu la r t ech n ology Who are we? •Director of Technology Development: Dr Peter Estibeiro PhD Molecular Biology (Leicester) 1987 Senior research fellow and lecturer (Edinburgh) 1995-1999 Founder and Director of ExpressOn BioSystems 1999- •Director of Operations: Dr Eleanor Barnard PhD Molecular Virology (Glasgow) 1997 Research Fellow (Edinburgh) 1996-2000 Co-founder and Director of ExpressOn BioSystems 1999- •Non-executive Director: to be announced •Commercial Director: to be appointed in 2001 ExpressOn BioSystems Acces s t o m olecu la r t ech n ology Why are we here? • £100,000 Edinburgh Technology Fund (ETF) equity investment By mid-2001: validated proprietary technology portfolio of IP & commercialisation strategy • £2 million investment 2001-2003: relocate to Midlothian biotech cluster strengthen management team develop proprietary software scale-up to full commercial design process employ additional scientific staff ExpressOn BioSystems Acces s t o m olecu la r t ech n ology